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BACKGROUND: Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors
(PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of vatalanib in advanced
gastrointestinal stromal tumour (GIST) resistant to imatinib or both imatinib and sunitinib.
PATIENTS AND METHODS: Forty-five patients whose metastatic GIST had progressed on imatinib were enrolled. Nineteen (42.2%)
patients had received also prior sunitinib. Vatalanib 1250mg was administered orally daily.
RESULTS: Eighteen patients (40.0%; 95% confidence interval (CI), 25.7–54.3%) had clinical benefit including 2(4.4%) confirmed partial
remissions (PR; duration, 9.6 and 39.4 months) and 16 (35.6%) stabilised diseases (SDs; median duration, 12.5 months; range,
6.0–35.6þ months). Twelve (46.2%) out of the 26 patients who had received prior imatinib only achieved either PR or SD
compared with 6 (31.6%, all SDs) out of the 19 patients who had received prior imatinib and sunitinib (P¼0.324). The median time
to progression was 5.8 months (95% CI, 2.9–9.5 months) in the subset without prior sunitinib and 3.2 (95% CI, 2.1–6.0) months
among those with prior imatinib and sunitinib (P¼0.992). Vatalanib was generally well tolerated.
CONCLUSION: Vatalanib is active despite its narrow kinome interaction spectrum in patients diagnosed with imatinib-resistant GIST or
with imatinib and sunitinib-resistant GIST.
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Imatinib mesylate is currently regarded as the standard first-line
treatment of advanced gastrointestinal stromal tumour (GIST),
since the responses achieved are usually durable and imatinib is
generally relatively well tolerated (Demetri et al, 2002; Verweij
et al, 2004). Unfortunately, most GISTs ultimately progress despite
continued imatinib administration, the median time to disease
progression being B2 years as calculated from the date of
initiation of therapy (Blanke et al, 2008). Sunitinib malate has been
approved as the second-line treatment option for patients who do
not tolerate imatinib or whose disease progresses on imatinib. In
this setting, the objective response rate to sunitinib was 7% and the
median time to progression (TTP) 6.3 months in a randomised
prospective clinical trial that compared single-agent sunitinib with
placebo (Demetri et al, 2006). When sunitinib is administered at
the registered dose, 50mg daily for 4 weeks followed by a 2-week
break, or at a continuous dose of 37.5mg daily, it is frequently
associated with adverse effects that include mucositis, fatigue,
diarrhea, hand–foot skin reaction, hypothyroidism and cardiac
toxicity (Demetri et al, 2006). There is a need for well-tolerated and
effective treatments for GIST patients whose disease ceases to
respond to imatinib.
Vatalanib (PTK787/ZK 222584; Bayer Schering Pharma AG,
Berlin; Novartis, East Hanover, NJ, USA) is an oral tyrosine kinase
inhibitor (TKI) that inhibits the two key kinases that are often
mutated in GIST, KIT and the platelet-derived growth factor
receptor-a (PDGFRa), and all three isoforms of the vascular
endothelial growth factor receptors (VEGFR-1 [Flt-1], VEGFR-2
[KDR] and VEGFR-3 [Flt-4]) (Wood et al, 2000). Vatalanib may
thus be effective in the treatment of GIST. Imatinib is an inhibitor
of several kinases including KIT, PDGFRa and -b, bcr-Abl, Abl,
Arg and the colony-stimulating factor-1 receptor (FMS), and
similarly sunitinib inhibits many kinases, including KIT, PDGFRa,
PDGFRb, CSF-1R, Fms-like tyrosine kinase-3 receptor (FLT-3), the
receptor encoded by the ret proto-oncogene (RET), and VEGFR-1,
VEGFR-2 and VEGFR-3. In a study conducted by Karaman et al
(2008), the interaction of vatalanib with the human kinome was
more limited compared with imatinib, sunitinib, sorafenib or
dasatinib, which suggests that vatalanib might be well tolerated.
Since vatalanib blood level reaches peak concentration (Tmax)i n
1.0–2.5h and it has a short a half-life of 4.5h, it does not
accumulate at the steady state with once-daily (QD) dosing.
We have earlier reported treatment results with vatalanib of 15
patients diagnosed with advanced GIST whose disease progressed
on imatinib (Joensuu et al, 2008). Vatalanib administered at the
dose of 1250mg orally QD was found active; two (13%) out of the
15 patients achieved partial remission (PR) and eight (53%) had
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sstable disease (SD) X3 months, and the median TTP was 8.5
months. As predicted by its limited kinome interaction profile,
vatalanib was well tolerated. Here, we report the treatment results
of 45 patients whose GIST progressed on imatinib and often also
on sunitinib. We observed clinical activity of vatalanib in these
patient populations, suggesting that broad kinase inhibition
spectrum inhibitors may not always be necessary for attaining
clinical activity in imatinib-resistant GIST.
PATIENTS AND METHODS
Patients
Patients were eligible to this phase II, prospective, open-label,
multicentre (four centres) study provided that they had histolo-
gically, cytologically or radiologically confirmed metastatic GIST
with at least one measurable tumour lesion as determined by
Response Evaluation Criteria in Solid Tumours (RECIST) v. 1.0
(Therasse et al, 2000). We required that GIST was resistant to
imatinib (objective evidence of progression after X4 weeks’
treatment) or that the patient did not tolerate imatinib. Further
inclusion criteria were age X18 years, a World Health Organiza-
tion performance status of 0–2, blood neutrophil count (ANC)
X1.5 10
9l
–1, platelet count X100 10
9l
–1, haemoglobin
X9.0gdl
–1, aspartate aminotransferase and alanine aminotrans-
ferase p3.0  upper limit of normal (ULN) (p5.0 ULN if liver
metastases were present), total urinary protein collected in 24h
p500mg, serum creatinine p1.5 ULN, 24h creatinine clearance
X50ml per minute and life expectancy over 3 months. Patients
were excluded if they received chemotherapy o4 weeks before
study entry, had received a cumulative dose of doxorubicin
4560mgm
–2 or epirubicin 4800mgm
–2, had acute or chronic
liver disease or were taking warfarin sodium.
The study protocol allowed expansion of the trial if clinical
efficacy was observed in more than three out of the first 15 patients
entered in the study, which condition was met (Joensuu et al,
2008). The expanded protocol allowed inclusion of also patients
who had progressed on both imatinib and sunitinib. Patients who
had received another KDR inhibitor therapy than sunitinib were
excluded. None of the patients had received adjuvant imatinib.
Written informed consent was obtained from each patient
before study inclusion. The protocol was approved by an
Independent Ethics Committee, and each investigator conducted
the trial (ClinicalTrials.gov identifier NCT00117299) in accordance
with the Declaration of Helsinki.
Vatalanib administration
Vatalanib 1250mg (five 250mg tablets) was administered orally
QD on a continuous basis until progressive disease (PD) or
unacceptable toxicity occurred in study patient nos. 1–15. The
total 1250mg daily dose was divided into two and administered
twice daily (BID) in the subsequent patients (nos. 16–45) to better
adjust dosing for the short blood half-life of vatalanib; 500mg (two
tablets) were taken in the morning and 750mg (three tablets) in
the evening B12h apart each day.
Study procedures
Adverse events were recorded and physical examination was
performed at each visit performed at 2- to 8-week intervals.
Treatment was interrupted if patients exhibited Common Toxicity
Criteria (CTC) grade 4 hypertension, ataxia or dizziness, or
neutropenia; grade 3 transaminase or bilirubin elevation, ataxia or
dizziness 410 days’ duration (related to vatalanib), or any other
grade 3 or 4 toxicity other than nausea or vomiting; grade X2
proteinuria (X1.0g) or haematuria; serum creatinine X2.0 
ULN; or thrombocytopenia with platelet count p25 10
9l
–1.I f
toxicities resolved to CTCpgrade 1 with ANC X1.5 10
9l
–1 and
platelets X100 10
9l
–1, the dose was scheduled to be reduced to
1000mg for the first episode of toxicity and to 750mg for the
second. Patients who exhibited a third episode of toxicity or had
treatment delayed X3 weeks had vatalanib administration
discontinued.
Tumour response was assessed using RECIST 1.0 (Therasse
et al, 2000). Criteria required for determining complete response
(CR) or PR had to be present X4 weeks. Computed tomography or
magnetic resonance imaging was performed at baseline, on study
week 4, 8, 12 and every 8 weeks thereafter. The same imaging
method was required to be used in response assessments. Serum
chemistry was performed at baseline and thereafter at 1- to 4-week
intervals, and serum coagulation panel at baseline and on week 4.
Chest radiographs were obtained at baseline, week 4 and week 12;
and electrocardiograms at baseline, week 4, week 12 and every 8
weeks thereafter. Urinalyses were performed at baseline, week 2,
week 4 and every 4 to 8 weeks thereafter. KIT and PDGFRA
mutation analyses were not required for study entry.
Statistical analysis
The first 15 patients who were the subject of the prior report
(Joensuu et al, 2008) are included in the current analysis that uses
a two-stage design (n1¼15, n2¼30). Subsequent analyses were
performed separately in the subgroups of patients with and
without prior sunitinib therapy. We were interested to detect a
clinical benefit rate (the primary end point) different from 0.20.
Accepting an a¼0.05 (type I error), 15 patients in the first stage
and 30 patients in the second stage (45 patients overall) would
provide 81% power at P¼0.38 based on a one sample two-stage
design (O’Brien and Fleming use function) with unequal sample
sizes per stage.
Response (CRþPR) and SD rates were calculated by intent to
treat. Response duration and duration of SD were calculated from
the date of first occurrence to the date of disease progression,
death or last follow-up. Disease was required to fulfil the criteria of
SD for a minimum duration of 3.0 months in order to be
categorised as SD. Clinical benefit was defined as confirmed or
unconfirmed CR or PR, or SD X3.0 months.
Frequency tables were analysed using the w
2 test. Cumulative
survival was estimated using the Kaplan–Meier life-table method,
and survival between groups was compared using the log-rank test.
Time to progression was defined as the time interval from the date
of treatment initiation to the date of PD or death due to cancer,
and patients who were alive without disease progression were
censored on the date of last follow-up. All P-values are two-sided.
RESULTS
Forty-five patients with advanced GIST were enrolled between
August 2004 and November 2007 in the study. The patient
population was predominantly (76%) male and had a median age
of 61 years (range, 19–82), and most had a good performance
status (0 or 1; Table 1). Most had received imatinib at least 800mg
daily with either PR or SD as their best response. Only one (2.2%)
patient did not tolerate imatinib. Nineteen (42.2%) had received
prior sunitinib in addition to prior imatinib.
Patients underwent treatment with vatalanib for a median of 3.1
months (range, 0.03–44.0 months). Forty-three (95.6%) patients
have completed the study, 39 (90.7%) of whom had PD upon
discontinuation. The remaining four patients discontinued the
study due to sudden death (n¼1), adverse effect (n¼2) or
withdrawal of consent (n¼1). Two patients had an ongoing SD
and continued to receive vatalanib 21.8 and 35.6 months after
study entry.
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sTwo (4.4%) patients achieved a confirmed PR as best response
(three further patients had unconfirmed PR), and 16 (35.6%) had
SD lasting for X3 months after study entry (Figure 1). Overall, 18
patients had a clinical benefit (40.0%; 95% confidence interval
(CI), 25.7–54.3%). The PRs lasted for 9.6 and 39.4 months, and the
median duration of the 16 SDs was 12.5 months (95% CI, 9.1–25.8
months; range, 6.0–35.6þ months). Twelve (46.2%) out of the 26
patients who did not receive prior sunitinib achieved either a PR
(n¼2, 7.7%) or SD (n¼10, 38.5%) compared with six (31.6%, all
SDs) out of the 19 patients who had received prior imatinib and
sunitinib (P¼0.324). The median duration of SD among the
patients who had not received prior sunitinib was 9.9 months
(range, 6.3–33.8 months), and among those with prior both
imatinib and sunitinib therapy 19.7 months (range, 6.0–36.5þ)
months.
The median TTP was 4.5 months (95% CI, 2.9–8.4 months). The
median TTP was 5.8 months (95% CI, 2.9–9.5 months) in the
subset of patients who had not received prior sunitinib and 3.2
months (95% CI, 2.1–6.0 months) among those exposed to prior
imatinib and sunitinib (P¼0.992; Figure 2).
Vatalanib 1250mg per day was generally well tolerated, and no
permanent dose reductions were required. The dose was
temporarily reduced in 39 (87%) out of the 45 patients for 1 to
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Figure 1 A waterfall plot showing the minimum relative change in
tumour mass compared with baseline in 45 GISTs treated with vatalanib.
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Figure 2 (Upper panel) Time to progression (all patients). (Lower
panel) Time to progression of 26 patients treated with prior imatinib only
and 19 patients with prior imatinib and sunitinib. Patients censored are
indicated with a bar.
Table 1 Patient characteristics
Number of patients (N¼45)
Characteristic n (%)
Age, median (range) 61 (19–82)
Gender
Male 34 (75.6)
Female 11 (24.4)
WHO performance status at baseline
0 24 (57.1)
1 17 (40.5)
2 1 (2.4)
N.A. 3
Primary site of lesion
Small intestine 18 (40.0)
Stomach 18 (40.0)
Rectum 2 (15.6)
Other 7 (4.4)
Metastatic sites (n¼102)
Liver 39 (38.2)
Peritoneum/omentum 19 (18.6)
Intra-abdominal, other 23 (22.5)
Other/unknown 18 (17.6)
Ascites/pleural fluid 3 (2.9)
Highest prior imatinib dose, mg per day
400 2 (4.4)
600 6 (13.3)
800 36 (80.0)
1000 1 (2.2)
Best prior response to imatinib
CR 0 (0.0)
PR 17 (43.6)
SD 15 (38.5)
PD 7 (17.9)
N.A. 6
Prior treatment with sunitinib
Yes 19 (42.2)
No 26 (57.8)
Best prior response to sunitinib (n¼19)
CR 0 (0.0)
PR 3 (16.7)
SD 10 (55.6)
PD 5 (27.8)
N.A. 1
Abbreviations: WHO¼World Health Organization; N.A.¼data not available;
CR¼complete response; PR¼partial response; SD¼stable disease; PD¼progres-
sive disease.
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s64 days as per protocol due to an adverse event or laboratory test
abnormality (n¼4). After the reductions, the dose was returned
back to 1250mg per day.
Adverse events reported for X2 patients, regardless of the CTC
grade, are presented in Table 2. The most frequently reported adverse
events were hypertension (n¼13, 28.9%), nausea (n¼13, 28.9%),
dizziness (n¼11, 24.4%), proteinuria (n¼9, 20.0%), abdominal pain
(n¼8, 17.8%) and diarrhea (n¼8, 17.8%). Most adverse events were
mild (grade 1 or 2); only 23 severe (grade 3 or 4) adverse events were
recorded during the study. Of these, four were grade 4 in severity
(hypercalcemia, pain, pulmonary embolism, sudden death; n¼1
for each), of which only pulmonary embolism was possibly related
to study medication. Only one patient was diagnosed with
hypothyroidism and none with hand–foot skin reaction.
DISCUSSION
Vatalanib turned out to be active as second-line or third-line
treatment of advanced imatinib-resistant or imatinib and suniti-
nib-resistant GIST. To our knowledge, the current study is the only
one that has addressed vatalanib in the treatment of GIST. The
results of the present expanded cohort are consistent with those of
the first 15 patients included in the series, in which subset only
prior imatinib was allowed before study entry (Joensuu et al,
2008). Although the PR rate was low (4.4%), many patients (35.6%)
had SD lasting for X6 months, suggesting substantial vatalanib
activity. Of note, 6 (31.6%) out of the 19 patients who progressed
both on imatinib and sunitinib achieved SD that lasted for a
median of 19.7 months (range, 6.0–36.5 months), suggesting that
vatalanib has clinically meaningful activity in some patients whose
disease no longer responds to imatinib and sunitinib. In the subset
of patients who had been exposed only to prior imatinib (n¼26),
the response rate to vatalanib was 7.7% and further 38.5% of
patients had SD. These figures resemble remarkably closely those
obtained with sunitinib in a comparative patient population. PR
rates ranging from 7 to 13% and SD rates raging from 33 to 59%
were achieved with sunitinib in patients who had imatinib-
resistant GIST or who were intolerant to imatinib (Maki et al, 2005;
Demetri et al, 2006; George et al, 2009). Similarly, the median TTP
achieved in the current study with vatalanib in this patient group
(5.8 months) is roughly similar to the 6.3 months achieved with
sunitinib (Demetri et al, 2006). Yet, comparisons between different
series need to be interpreted with caution.
Vatalanib was in general very well tolerated. The most frequent
adverse effects were rarely graded severe. Hypertension occurred
in 28.9% of the patients, but it was generally easily manageable. No
patient with severe dizziness, nausea or proteinuria was reported,
and none of these adverse effects resulted in treatment disconti-
nuation or dose reduction. Dizziness typically occurred for a few
hours after taking vatalanib, and could be managed either by
dividing the daily dose or by administration of vatalanib towards
the evening. Only four grade 4 adverse events were recorded
during the study, of which one, pulmonary embolism, was possibly
vatalanib related. One patient died unexpectedly during the study,
but the cause of death was probably unrelated to the study drug.
We recorded no patients with hand–foot skin reaction or
mucositis, which are common adverse effects of sunitinib, and
hypothyroidism and fatigue were also rare and classified mild in
severity. Safety of vatalanib thus appears to compare well with that
of sunitinib or the higher doses of imatinib (Verweij et al, 2004),
although no direct comparative data are available.
Vatalanib may not be developed further in clinical trials, mainly
because it did not improve survival in combination with
chemotherapy in two large prospective randomised trials
(CONFIRM-1 and CONFIRM-2) carried out in advanced colorectal
cancer (Hecht et al, 2011; Van Cutsem et al, 2011). This may be
unfortunate considering the few treatment options available for
imatinib-resistant GIST, since not all GIST patients tolerate
sunitinib well, and effective and well-tolerated third-line treat-
ments are urgently needed. Furthermore, the present results are of
particular interest and important from a hypothesis-generating
point of view as well. Vatalanib is a narrow-spectrum TKI
(Karaman et al, 2008), and yet, it had activity in imatinib and
sunitinib-resistant GIST despite that both imatinib and sunitinib
interact with the kinome more broadly than vatalanib. This
suggests that KIT (and PDGFRA) still remains a viable target in
imatinib and sunitinib-resistant GIST. Kinase inhibition will likely
result in the greater toxicity the more kinases are inhibited. Since
inhibition of many kinases may thus not always be required for
significant clinical activity in imatinib-resistant GIST, it may be
possible to develop well tolerated and yet effective inhibitors for
imatinib-resistant GIST. The novel switch pocket inhibitors may
be one such approach (Heinrich et al, 2010).
We did not collect tissue for KIT and PDGFRA mutation
analyses, which may be considered a limitation of the study. This
limitation may, however, be minor, because acquired KIT
mutations are common in imatinib-resistant GIST reducing the
applicability of the primary tumour mutation analysis (Heinrich
et al, 2003), and because recent studies show that multiple
acquired mutations are often present in imatinib-resistant GIST
(Wardelmann et al, 2006; Liegl et al, 2008). In imatinib-resistant
disease, the number of acquired KIT mutations detected may be
dependent on the number of biopsies taken, several acquired
mutations are often detected in the same individual in different
metastases, and sometimes even one metastasis may contain more
Table 2 Adverse events occurring in at least 4% of patients
Toxicity by grade
Grade 1 or 2
(N¼45)
Grade 3
(N¼45)
Grade 4
(N¼45)
Total
(N¼45)
Adverse event n (%) n (%) n (%) n (%)
Hypertension
a 8 (17.8) 4 (8.9) 0 13 (28.9)
Nausea 13 (28.9) 0 0 13 (28.9)
Dizziness 11 (24.4) 0 0 11 (24.4)
Proteinuria 9 (20.0) 0 0 9 (20.0)
Abdominal pain 6 (13.3) 2 (4.4) 0 8 (17.8)
Diarrhea 7 (15.6) 1 (2.2) 0 8 (17.8)
Asthenia 6 (13.3) 1 (2.2) 0 7 (15.6)
Dyspepsia 5 (11.1) 0 0 5 (11.1)
Pyrexia 5 (11.1) 0 0 5 (11.1)
Upper abdominal pain 5 (11.1) 0 0 5 (11.1)
Vomiting 5 (11.1) 0 0 5 (11.1)
Fatigue 4 (8.9) 0 0 4 (8.9)
Headache 3 (6.7) 1 (2.2) 0 4 (8.9)
Pain 3 (6.7) 0 1 (2.2) 4 (8.9)
Anaemia 3 (6.7) 0 0 3 (6.7)
Constipation 3 (6.7) 0 0 3 (6.7)
Hyperhidrosis 3 (6.7) 0 0 3 (6.7)
Visual disturbance 3 (6.7) 0 0 3 (6.7)
ALT increased 0 2 (4.4) 0 2 (4.4)
Anorexia 2 (4.4) 0 0 2 (4.4)
Arthralgia 2 (4.4) 0 0 2 (4.4)
AST increased 1 (2.2) 1 (2.2) 0 2 (4.4)
Dysphonia 2 (4.4) 0 0 2 (4.4)
Epitaxis 2 (4.4) 0 0 2 (4.4)
Insomnia 2 (4.4) 0 0 2 (4.4)
Myalgia 2 (4.4) 0 0 2 (4.4)
Oedema, peripheral 2 (4.4) 0 0 2 (4.4)
Pulmonary embolism 0 1 (2.2) 1 (2.2) 2 (4.4)
Polyuria 2 (4.4) 0 0 2 (4.4)
Weight decreased 2 (4.4) 0 0 2 (4.4)
Abbreviations: ALT¼alanine aminotransferase; AST¼aspartate aminotransferase;
CTC¼Common Toxicity Criteria.
aCTC grade missing for one event.
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sthan one resistance mutation (Liegl et al, 2008). Therefore, unlike
in the first-line treatment of advanced GIST or in the adjuvant
setting where mutation analysis is of importance, mutation
analysis appears to have limited value in selection of systemic
treatment for imatinib-resistant GIST.
Vatalanib was administered QD in the first part of the study
(patients 1–15), but BID in the expansion part, because vatalanib
has a short half-life (4.5h) and the twice daily administration
might have increased efficacy. We did not, however, observe a
significant difference in efficacy between the two dosing regimens,
but this may have been confounded by the amended patient
selection criteria, where prior sunitinib was allowed in the
expansion part of the study. In a phase I study where
150–1000mg of vatalanib was given BID to patients with solid
tumours (Thomas et al, 2005), its exposure increased with dosing
up to 500mg BID and reached a plateau at higher doses, suggesting
that total daily doses X1000mg are optimal for clinical trials.
We conclude that vatalanib is active in patients who have
imatinib-resistant GIST or imatinib and sunitinib-resistant GIST.
Although only a few PRs were achieved, several of the SDs were
durable. The overall efficacy results resemble those obtained with
sunitinib, the only currently approved second-line therapy for
imatinib-resistant GIST. Of note, vatalanib was generally well
tolerated, which is in line with its narrow kinase interaction
spectrum. The results suggest that relatively narrow-spectrum,
well-tolerated TKIs may be effective in the treatment of imatinib
and sunitinib-resistant GIST, and that mutated KIT may thus
frequently remain a key target in advanced GIST that has become
resistant to one or more TKIs.
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